WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 ...

Relmada Therapeutics recently reported past 12‑month interim Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A novel GLP-1 and amylin receptor agonist reduced HbA1c ...

Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...